Aumed, a.s., Komořanská 326/63, 143 14 Praha - Modřany, Česká republika

+420 603 587 701 English

Successful completion of the OPPIK project “RESEARCH AND DEVELOPMENT OF A NEW WHOLE-CELL VACCINE AGAINST WHOOPING COUGH”

Prototyp černý kašel

This year, company AUMED a.s. successfully completed a multi-year project of the OPPIK program entitled “RESEARCH AND DEVELOPMENT OF A NEW WHOLE-CELL VACCINE AGAINST WHOOPING COUGH” (project number CZ.01.1.02 / 0.0 / 0.0 / 15_019 / 0005074).

The project addressed a problem caused by the replacement of the classic whole-cell pertussis vaccine by an acellular pertussis vaccine.

The causative agent of whooping cough – Bordetella pertussis is one of the epidemiologically important bacteria. Whooping cough (pertussis) is a disease of the respiratory tract. Global infant mortality from Bordetella pertussis infection is approaching 200,000 deaths per year. Whooping cough can affect people of all ages, but the most endangered are children and the elderly. In the Czech Republic, around 1,000 people get sick each year with a mortality rate of around 5–7 individuals.

In our republic, the whole-cell pertussis vaccine has been widely used since the 1950s. Due to acute side effects, it has been gradually replaced by a non-cellular (acellular) vaccine since 2007. Vaccination with a whole-cell vaccine produces the same immunity as would occur after a disease. It includes, among other things, substances against bacterial toxins. The non-cellular vaccine does not contain the antigen of this toxin, so no antibodies will be produced against it after vaccination. In the case of pertussis infection, in terms of the spread of the infection, it proceeds as in the first contact with the infection in an unvaccinated individual; Bordetella multiplies in it and can spread to the environment (a person thus becomes a carrier). Nevertheless, this vaccination is also important, because the symptoms of the disease are then much weaker or may not occur at all. Acellular vaccines are now proving to be problematic in practice also in their time-limited immunoprotective function (relatively short time protection).

The main output of the project are samples of the new whole-cell vaccine. The samples are now in the process of stability studies. We assume that the new whole-cell vaccine samples will be further subjected to a series of additional tests (preclinical or clinical) required by the European Medicines Agency before the new vaccine can be placed on the market.

MORE ARTICLES

AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”

29. 11. 2022

AUMED, a.s. successfully completed the 1st stage of the project entitled “Transferfaktor TFI – Medicinal product”, registration number CZ.01.1.02/0.0/0.0/20_318/0026008. As…

AUMED, a.s. presented phage research at the Phages 2022 conference in Oxford

26. 09. 2022

AUMED participated in the 12th annual bacteriophage conference in Oxford, which is the only European phage conference with such a…

AUMED a.s. founded a new company AUMED Immunology a.s.

19. 09. 2022

AUMED a.s. founded a new company AUMED Immunology a.s.. AUMED, a.s. is the sole shareholder of the newly formed company….

Research projects of Aumed, a.s. are financed by the European Structural Funds:
Research and development of a new pertussis vaccine
Transfer factor — research and development of a new medical form
Production of diagnostic kit for covid-19 on the lamp principle
TFI Transfer Factor – Medicine

and with financial support from the state budget through the Ministry of Industry and Trade in the TRIO program:
Research and development of a new oral administration of vaccine

European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness


Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s